Welcome to our dedicated page for Greenwich Lifesciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich Lifesciences stock.
Greenwich LifeSciences, Inc. reports developments as a clinical-stage biopharmaceutical company focused on FLAMINGO-01, a Phase III clinical trial evaluating GLSI-100 as an immunotherapy intended to prevent breast cancer recurrences. GLSI-100 combines the GP2 peptide with GM-CSF and is described by the company as a Fast Track designated program.
Recurring news includes FLAMINGO-01 clinical-site activity, oncology conference abstracts and posters, open-label immune-response and recurrence-rate data, patent-claim updates tied to GP2, at-the-market equity financing activity, and SEC reporting or Nasdaq compliance matters related to periodic filings.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has initiated the Flamingo-01 Phase III clinical trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences post-surgery. Clinical site activation is in progress across multiple hospitals, alongside site initiation training for clinical staff. The trial intends to enroll approximately 500 patients, with initial Phase III data expected by year-end. The company maintains a strong cash position, allowing for strategic financial maneuvers. CEO Snehal Patel indicated that results from the trial could validate prior Phase IIb findings, which showed no recurrences in treated patients over 5 years.
Greenwich LifeSciences (NASDAQ: GLSI) announced its well-capitalized status with a cash balance of $19.7 million as of March 31, 2022. The company aims to transition to an investment banking syndicate through a recent ATM sale agreement to use opportunistically. The commencement of the Phase III clinical trial, Flamingo-01, is expected to gradually increase the burn rate. Updates on the trial and ongoing studies will be provided soon, with a focus on immunotherapy GLSI-100 for breast cancer prevention.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) announced that the FDA has lifted the clinical hold on its Flamingo-01 Phase III clinical trial, allowing the company to proceed. The hold was previously imposed due to manufacturing and pharmacy process issues related to the candidate GP2. Following successful discussions and testing with the FDA, these concerns have been addressed. The trial is now moving forward with site initiation visits underway, and further updates on the trial's progress will be provided.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has announced the suspension of its share repurchase program. Previously, the Company repurchased around 520,000 shares for approximately $7.5 million. Following these transactions, GLSI has about 12.8 million shares of common stock outstanding. This decision comes amid considerations that may impact future financial strategies.
Greenwich LifeSciences (GLSI) has announced the resumption of its Stock Repurchase Program, authorized by its board. The program allows the company to buy back shares in the open market or through private transactions, depending on market conditions. With approximately $4.5 million remaining under this program, Greenwich had 12,951,453 shares outstanding as of March 31, 2022. The company is also advancing its clinical trial for GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences.
Greenwich LifeSciences (NASDAQ: GLSI) is progressing towards initiating the FLAMINGO-01 Phase III trial focused on GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences. FDA reviews are underway related to manufacturing plans that led to a clinical hold. Site contracts with major U.S. oncology networks are finalized, enabling patient enrollment. Upcoming presentations at the ASCO Annual Meeting aim to enhance outreach. The trial, designed to evaluate 500 patients, aims for significant efficacy in preventing breast cancer recurrence.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) announced CEO Snehal Patel will participate in several key conferences, including the H.C. Wainwright Global Investment Conference (May 23-26, 2022) in Miami, the ASCO Annual Meeting (June 3-7, 2022) in Chicago, the Jefferies Healthcare Conference (June 8-10, 2022) in New York, and the BIO International Convention (June 13-16, 2022) in San Diego. The company focuses on GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences. Notably, the Phase III FLAMINGO-01 trial targets HER2/neu positive patients.
Greenwich LifeSciences (GLSI) announced key results from two Phase IIb clinical trials presented at the AACR Annual Meeting 2022. The trials evaluated GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences. Abstract CT166 highlighted that GLSI-100 elicited a robust immune response in HER2+ patients, achieving a 100% 5-year disease-free survival (DFS) rate for treated patients compared to 89.4% for controls (p = 0.0338). Abstract CT161 indicated that a positive GP2 immune response correlates with increased recurrence risk, offering predictive potential for patient outcomes.
Greenwich LifeSciences announced the registration of its Phase III clinical trial, Flamingo-01, on clinicaltrials.gov. This trial, testing GLSI-100, aims to prevent breast cancer recurrences in patients post-surgery. The trial will involve approximately 600 patients and has the potential for significant patent extensions if successful. The company will present three clinical trial posters at the upcoming AACR Annual Meeting 2022 from April 8-13, providing updates on trial progress and further recruitment of clinical sites.
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that CEO Snehal Patel will present at the 2022 BIO CEO & Investor Conference on February 14, 2022. The conference, from February 14-17, focuses on biotech networking and investment opportunities. Greenwich is developing GLSI-100, an immunotherapy to prevent breast cancer recurrences, currently in the FLAMINGO-01 Phase III clinical trial targeting HER2-positive patients. The trial aims to assess effectiveness based on interim analyses of patient outcomes.